- Home
- AMGN vs INTU Comparison
AMGN vs INTU Comparison
Compare AMGN & INTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- INTU
- Stock Information
- Founded
- AMGN 1980
- INTU 1983
- Country
- AMGN United States
- INTU United States
- Employees
- AMGN N/A
- INTU N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- INTU Computer Software: Prepackaged Software
- Sector
- AMGN Health Care
- INTU Technology
- Exchange
- AMGN Nasdaq
- INTU Nasdaq
- Market Cap
- AMGN 156.2B
- INTU 172.8B
- IPO Year
- AMGN N/A
- INTU 1993
- Fundamental
- Price
- AMGN $265.86
- INTU $653.88
- Analyst Decision
- AMGN Buy
- INTU Buy
- Analyst Count
- AMGN 19
- INTU 20
- Target Price
- AMGN $324.37
- INTU $718.89
- AVG Volume (30 Days)
- AMGN 2.7M
- INTU 1.4M
- Earning Date
- AMGN 05-01-2025
- INTU 05-22-2025
- Dividend Yield
- AMGN 3.58%
- INTU 0.64%
- EPS Growth
- AMGN 56.16
- INTU 9.41
- EPS
- AMGN 10.94
- INTU 10.70
- Revenue
- AMGN $34,126,000,000.00
- INTU $17,167,000,000.00
- Revenue This Year
- AMGN $7.19
- INTU $14.95
- Revenue Next Year
- AMGN $2.37
- INTU $12.25
- P/E Ratio
- AMGN $24.29
- INTU $61.05
- Revenue Growth
- AMGN 15.56
- INTU 13.73
- 52 Week Low
- AMGN $253.30
- INTU $532.65
- 52 Week High
- AMGN $346.85
- INTU $714.78
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- INTU 65.41
- Support Level
- AMGN $268.81
- INTU $622.94
- Resistance Level
- AMGN $291.61
- INTU $662.49
- Average True Range (ATR)
- AMGN 7.54
- INTU 13.75
- MACD
- AMGN -0.76
- INTU 4.82
- Stochastic Oscillator
- AMGN 0.76
- INTU 90.54
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.